Gershenson D M, Copeland L J, Kavanagh J J, Stringer C A, Saul P B, Wharton J T
Department of Gynecology, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston.
Obstet Gynecol. 1987 Nov;70(5):765-9.
From September 1981 until June 1986, eight patients with metastatic ovarian stromal tumors were entered into a prospective phase II study to determine the efficacy of a chemotherapy regimen combining cisplatin, doxorubicin, and cyclophosphamide. Patients received cisplatin 40-50 mg/m2 intravenously (IV), doxorubicin 40-50 mg/m2 IV, and cyclophosphamide 400-500 mg/m2 IV, all on day 1 every 28 days. The median age was 43 years (range 24-65 years). Two patients had stage II disease, one had stage III, and five had recurrent disease (original stage: four stage I and one stage III). The median number of chemotherapy cycles was six (range four to 14). Three patients (38%) had a complete response to therapy (two confirmed by second-look laparotomy), and two patients (25%) achieved a partial response (one verified by second-look laparotomy). The overall response rate was 63%. Toxicity was minimal. Four patients are disease-free at 13+ to 48+ months, one patient is alive with disease at six+ months, and three patients are dead of tumor at four, 17, and 36 months from the start of chemotherapy. These results indicate that the combination of cisplatin, doxorubicin, and cyclophosphamide has modest activity in the treatment of metastatic ovarian stromal tumor.
从1981年9月至1986年6月，8例转移性卵巢间质瘤患者进入一项前瞻性II期研究，以确定顺铂、阿霉素和环磷酰胺联合化疗方案的疗效。患者每28天的第1天静脉注射顺铂40 - 50mg/m²、阿霉素40 - 50mg/m²和环磷酰胺400 - 500mg/m²。中位年龄为43岁（范围24 - 65岁）。2例患者为II期疾病，1例为III期，5例为复发性疾病（原分期：4例I期和1例III期）。化疗周期的中位数为6个（范围4 - 14个）。3例患者（38%）对治疗完全缓解（2例经二次剖腹探查证实），2例患者（25%）部分缓解（1例经二次剖腹探查证实）。总缓解率为63%。毒性极小。4例患者在13 +至48 +个月时无疾病，1例患者在6 +个月时带瘤存活，3例患者在化疗开始后4、17和36个月死于肿瘤。这些结果表明，顺铂、阿霉素和环磷酰胺联合应用在转移性卵巢间质瘤治疗中具有一定活性。
